Evaluation N-terminal pro-B-type natriuretic peptide and other biochemical parameters in heart failure with or without chronic kidney disease in Kirkuk city
Article Sidebar
Main Article Content
Abstract
Backgrounds: Individuals who are diagnosed with chronic kidney disease (CKD) are at a significantly increased risk of developing cardiovascular (CV) disease. Aim of the study: This study evaluated N-terminal pro-B-type natriuretic peptide, urea, creatinin, and albumin in heart failure with or without chronic kidney disease. Materials and methods: The study was done at Amal Dialysis Centre, General Kirkuk Hospital Lab and Azadi Teaching Hospital Lab. The age range of the participants was between 18-68 years old. The study was conducted from January to Augest 2023. The current study examined 90 participants that divided in to four groups as: G1=Kidney failure patients (n:23), G2=Heart failure patients (n:22), G3=Heart and kidney failure (n:23), and G4=apparently healthy normal individuals. Results: This study show highly significant increase NT Pro- BNP in G1, G2 and G3(123.88±22.73, 107.86± 20.15, 134.85± 26.05), as compared with G4 (67.19±18.44) at p-value<0.0008. While highly decrease albumin in G1,G2 and G3(4.318±0.486, 4.028±0.991, 5.500± 0.652), as compared with G4 (7.028± 0.991) at p-value <0.01Conclusion: This study concluded increase in NTpro Pro- BNP, urea and creatinin in all three groups as compared with control group and decrease in albumin level.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
[1] Al-Qady, N. M. H., and Shaban, R. K. (2020). Physiological and histological effect of Captopril on kidney and the protective role of Brassica nigra seed extract in male rats. Tikrit J. Pure Sci, 25 (6): 27-32. http://dx.doi.org/10.25130/tjps.25.2020.106 [2] Ibrahim, O. F. (2022). The Adverse consequence of covid-19 causing liver and kidney dysfunctions. Tikrit Journal of Pure Science, 27(5): 1-6. http://dx.doi.org/10.25130/tjps.27.2022.061 [3] Al-Din, W. A. M. I., & Salih, N. I. (2020). Using Serum Interleukin-18 (IL-18) as a Biomarker of Chronic Kidney Failure and its relationship with Prolactin Level. Tikrit Journal of Pure Science, 25(3): 14-18. http://dx.doi.org/10.25130/tjps.25.2020.106 [4] Castiglione, V. et al. (2022). Biomarkers for the diagnosis and management of heart failure. Heart failure reviews, 27(5): 625–643. https://doi.org/10.1007/s10741-021-10105-w
[5] Welsh, P. et al. (2022). Reference ranges for NT-proBNP (N-terminal pro-B-type natriuretic peptide) and risk factors for higher NT-proBNP concentrations in a large general population cohort. Circulation: Heart Failure, 15 (10): 957-967. https://doi.org/10.1161/circheartfailure.121.009427 [6] Chrysohoou, C., Konstantinou, K., and Tsioufis, K. (2024). The Role of NT-proBNP Levels in the Diagnosis and Treatment of Heart Failure with Preserved Ejection Fraction—It Is Not Always a Hide-and-Seek Game. Journal of Cardiovascular Development and Disease, 11(7): 225 https://doi.org/10.3390/jcdd11070225 [7] Wouk, N. (2021). End-stage renal disease: medical management. American family physician, 104(5): 493-499. https://www.aafp.org/ afp/2012/0401/p715.html. [8] Bereda, G. (2022). Definition, Stages, Risk Factors, Pathophysiology and Treatment of Acute Kidney Injury. Clinical Research and Clinical Case Reports, 2(5):1-7. http;//doi.org/12.2022/1.1048. [9] Goryacheva, O. A. et al. (2022). Heart failure biomarkers BNP and NT-proBNP detection using optical labels. TrAC Trends in Analytical Chemistry, 146(2): 116477.
https://doi.org/10.1016/j.trac.2021.116477 [10] Nishikimi, T., and Nakagawa, Y. (2021). Potential pitfalls when interpreting plasma BNP levels in heart failure practice. Journal of cardiology, 78(4):269-274. https://doi.org/10.1016/j.jjcc.2021.05.003 [11] Fu, S., et al. (2013). The ability of NT-proBNP to detect chronic heart failure and predict all-cause mortality is higher in elderly Chinese coronary artery disease patients with chronic kidney disease. Clinical interventions in aging, 3(8): 409–417409-417. https://doi.org/10.2147%2FCIA.S42700 [12] Van Kimmenade, R. R. et al. (2009). Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide: a mechanistic study in hypertensive subjects. Journal of the American College of Cardiology, 53(10), 884-890. https://doi.org/10.1016/j.jacc.2008.11.032 [13] Kragelund, C., Grønning, B., Køber, L., Hildebrandt, P., and Steffensen, R. (2005). N-terminal pro–B-type natriuretic peptide and long-term mortality in stable coronary heart disease. New England Journal of Medicine, 352(7), 666-675.
https://doi.org/10.1056/nejmoa042330 [14] James, S. K.,et al. (2003). N-terminal pro–brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation, 108(3), 275-281. https://doi.org/10.1161/01.cir.0000079170.10579.dc [15] Bruch, C., et al. (2008). Comparison of the prognostic usefulness of n-terminal pro–brain natriuretic peptide in patients with
heart failure with versus without chronic kidney disease. The American journal of cardiology, 102(4),469-47. https://doi.org/10.1016/j.amjcard.2008.03.082 [16] Hartmann, F., et al. (2004). Prognostic impact of plasma N-terminal pro–brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation, 110(13):1780-1786. https://doi.org/10.1161/01.cir.0000143059.68996.a7 [17] Uchikawa, T., Shimano, M., Inden, Y., and Murohara, T. (2014). Serum albumin levels predict clinical outcomes in chronic kidney disease (CKD) patients undergoing cardiac resynchronization therapy. Internal medicine, 53(6):555-561. https://doi.org/10.2169/internalmedicine.53.1209 [18] Kikuchi, H.et al. (2017). Combination of low body mass index and serum albumin level is associated with chronic kidney disease progression: the chronic kidney disease-research of outcomes in treatment and epidemiology (CKD-ROUTE) study. Clinical and experimental nephrology, 21(2),55-62. https://doi.org/10.1007/s10157-016-1251-2 [19] Shawkat, E. A., Abdulrahman, S. J., and Bakr, B. A. (2023). Assessment the Role of Erythropoietin, Hepcidin and Albumin in Patients with Chronic Kidney Disease in Kirkuk-Iraq. Kirkuk University Journal for Scientific Studies, 18(3),7-12. https://doi.org/10.32894/kujss.2023.141071.1104 [20] Uthamalingam, S.et al. (2010). Serum albumin and mortality in acutely decompensated heart failure. American heart journal, 160(6):1149-1155. https://doi.org/10.1016/j.ahj.2010.09.004 [21] Adlbrecht, C. et al. (2008). Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume. European heart journal, 29(19): 2343-2350 .
https://doi.org/10.1093/eurheartj/ehn359 [22] Liu, M. et al. (2012). Albumin levels predict survival in patients with heart failure and preserved ejection fraction. European journal of heart failure, 14(1), 39-44. https://doi.org/10.1093/eurjhf/hfr154 [23] Pasini, E., Opasich, C., Pastoris, O., and Aquilani, R. (2004). Inadequate nutritional intake for daily life activity of clinically stable patients with chronic heart failure. The American journal of cardiology, 93(8):41-43. doi:10.1016/j.amjcard.2003.11.009 [24] von Haehling, S., Lainscak, M., Springer, J., & Anker, S. D. (2009). Cardiac cachexia: a systematic overview. Pharmacology & therapeutics, 121(3):227-252 https://doi.org/10.1016/j.amjcard.2003.11.009 [25] Kadhim, H. M., Al-Ghanimi, H. H., and Al-Dedah, R. M. (2020, December). Haematological parameters and biochemical
indices in patients with chronic kidney disease before haemodialysis Al-Furat Al-Awsat Governorates / Iraq. In AIP Conference Proceedings, 2290(1): 1-13. https://doi.org/10.1063/5.0027856 [26] Jassim, M. M. (2024). Assessment biochemical parameters and electrolyte in renal failure patients on hemodialysis and Type 2 diabetes patients in Tikrit city. Journal of Education and Scientific Studies, 5(23): 67-75. https://doi. 05.23.05.2023.esj/52866.10/org.d